DEVISE-HD
Recruiting
Official title: Developing EVIdence for AntidepreSsant ChoicE to Treat Depression in Huntington’s Disease
(DEVISE-HD)
Study Design and Objectives
- Participants. Researchers aim to recruit 40 participants diagnosed with Huntington’s disease who experience mild to moderate depression.
- Measurements. Alongside tracking changes in depressive symptoms, researchers collect blood and cerebrospinal fluid samples. These samples help measure whether antidepressant treatment alters inflammation biomarkers linked to damaged cells.
- Goal. The findings will guide the design of a full-scale clinical trial to establish evidence-based depression treatments for Huntington’s disease patients
Phase:4
Subtype: Interventional Therapeutic
Primary Purpose: Treatment
Intervention Type: Drug
Primary Intervention: Sertraline
Mode of Action: Selective serotonin reuptake inhibitor(SSRI)
Duration: 24 weeks
Ages Eligible
for Study:
Age≥ 18;
Sexes Eligible
for Study:
All
Accepts Healthy Volunteers:
No
- Age and Genetic Status. Participants must be at least 18 years old with a confirmed positive genetic test for Huntington’s disease (CAG repeat expansion greater than 35) at any stage of the condition. [
- New Episode of Depression. Participants must report a new onset of low mood after being free of depressive symptoms for at least four months.
- Symptom Severity. Depressive symptoms must be mild to moderate, measured by a Problem Behaviours Assessment (PBAs) depressed mood score greater than 1 for both severity and frequency.
- Recent Antidepressant Use. Individuals currently taking an antidepressant or who have taken one within the past six months for any reason cannot join.
- Sertraline History. Anyone with a previous bad reaction, medical contraindication, or lack of response to sertraline is excluded.
- Other Medical Causes. Individuals with another brain illness, brain injury, or medication that a study doctor believes is causing the depressive symptoms are not eligible.
- Severe Symptoms or Safety Risks. People with severe depression (a PBAs severity score greater than 3) or suicidal thoughts cannot participate due to the higher clinical risk.
- Informed Consent. Participants must be able to understand the study details and provide valid informed consent. [1, 2]
LOCATIONS
COUNTRIES
United Kingdom
TRIAL SITE: Cardiff and Vale NHS Trust, Cardiff, UK
Email:DEVISEHD@cardiff.ac.uk
TRIAL SITE: Birmingham and Solihull Mental Health NHS Foundation Trust, Birmingham, UK
Email:DEVISEHD@cardiff.ac.uk
TRIAL SITE: Betsi Cadwaladr University Lhb Colwyn Bay Office, Wales, UK
Email:DEVISEHD@cardiff.ac.uk
